Introduction
In patients with myelodysplastic syndromes (MDSs), the chromosome abnormality not only confirms the clonality of the disease, [1] [2] [3] but also predicts the likelihood of progression into acute myeloid leukemia (AML) and overall survival (OS). [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] In 1997, the international prognostic scoring system (IPSS) has further emphasized that karyotype is one of the most important prognostic indicators in MDS and can be used along with bone marrow blast cell percentage and number/degree of peripheral cytopenia to subdivide patients into four subgroups having distinct clinical outcomes. 17, 18 However, conventional cytogenetics (CCs) reveals a normal karyotype in about 40-60% of patients. 1, 2, [6] [7] [8] [9] [10] [11] [12] [13] According to IPSS criteria, a normal chromosome pattern is considered prognostically favorable, even if it does not always indicate a positive clinical outcome. Therefore, new biological indicators are urgently needed in these patients in order to identify individuals at risk for AML evolution. Those novel markers may be discovered by fluorescence in situ hybridization (FISH), which can be carried out on nondividing cells and can identify minor clonal cell populations and cryptic abnormalities. Some FISH studies have already shown that occult defects (mainly monosomy 7, trisomy 8, deletions of the long arm of chromosome 5 or of chromosome 7) may be detected in chromosomally normal MDS. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] In addition, those reports suggested that FISH is a convenient complement to CC and have tried to define the most accurate 'FISH panel testing' for the analysis of chromosomally normal patients. [29] [30] [31] In the present study, we have performed FISH with seven single locus and four alphoid probes for the most frequent MDS chromosome aberrations in 57 patients, who were considered cytogenetically normal after the analysis of more than 20 metaphases. FISH was carried out in order to establish the incidence of occult abnormalities and to correlate them with FAB subtype, blast cell percentage, number of peripheral cytopenias, IPSS, OS and event-free survival (EFS).
Materials and methods

Diagnosis
All 57 chromosomally normal patients were diagnosed at the Division of Hematology, Policlinico San Matteo IRCCS, Pavia between January 1995 and December 2000. MDS diagnosis was made according to FAB criteria. Patients who developed MDS following exposure to carcinogenic agents or chemoradiotherapies carried out to treat other cancers, as well as nonmalignant disorders (eg autoimmune diseases) were excluded from the study. In every patient, bone marrow aspiration was an integral part of the diagnostic work-up and was repeated when necessary.
Treatments
A total of 47 patients received supportive treatment only, while nine underwent low-dose chemotherapy and one had intensive treatment due to hyperleukocytosis or disease progression.
Follow-up
Patients were seen at our outpatient clinic every 2-3 months, unless any change in their clinical condition occurred.
Conventional cytogenetics
Chromosome studies were carried out on bone marrow cells at diagnosis and during follow-up, using a trypsin-Giemsa banding technique. Metaphase cells were examined from short-term unstimulated cultures and karyotype was defined according to ISCN. 32 At least 20 normal metaphases were necessary to consider a patient cytogenetically normal.
FISH
FISH was carried out on cytogenetic preparations as previously reported. 33 Metaphase FISH was performed to establish whether the occult chromosome defect was undetected by CC due to either its truly submicroscopic nature or the poor quality of metaphases or leukemic cell kinetic features. FISH was performed with various commercially available cosmid probes (Appligene Oncor Q-BIOgene, Illkirch, France; Vysis, Downers Grove, IL, USA), which hybridize to genes or polymorphic loci specifically involved in MDS. The following probes were used: LSI 5q31 (EGR1), D7S522 (7q31), INT2 DNA probe (11q13.3), LSI 12p13 (ETV6), LSI 13 (13q14), TP53 DNA probe (17p13.1) and D20S108 (20q12). Each of these probes was simultaneously applied (cohybridized) with a different color-labelled probe (internal control). The combinations used were: 5q31 (spectrum orange) and D5S721:D5S23 (spectrum green); 7q31 (spectrum orange) and CEP 7 (spectrum green); INT2 DNA probe (rhodamine) and 11a (FITC); LSI 12p13 (spectrum green) and 21(q22) (spectrum orange); LSI 13 (13q14) (spectrum green) and LSI D20S108 (spectrum orange), TP53 DNA probe (rhodamine) and 17a (FITC). Therefore, probes specific for either the centromeric or for the short arm regions of chromosomes 5, 7, 11 and 17 were used as internal controls for cosmid probes exploring genes or polymorphic loci localized to these chromosomes. An ETV6 rearrangement was revealed by the LSI ETV6/AML-1 probe, and the AML-1 probe was used to confirm that effective hybridization had taken place. Simultaneous application of chromosome 8 alphoid probe with the LSI 13 (13q14) or the LSI D20S108 probes to detect band 13q14 or 20q12 losses confirmed effective hybridization. In order to determine the mean percentage of abnormal interphase cells, 200 nuclei from 10 normal controls were screened. Cells were considered monosomic when carrying one signal each for the internal control and target sequence probes, trisomic when carrying three signals for both probes, harboring a gene deletion when carrying two signals due to the internal control and only one signal due to the target sequence, harboring a gene duplication when carrying two signals due to the internal control and three signals due to the target sequence probe. Cutoff values were calculated after adding three times the standard deviation to the mean percentage of abnormal cells obtained. Interphase FISH (I-FISH) cutoff percentages were 5% for monosomy 7, 3% for trisomies 8 and 11, 8-14% for gene deletions and 4-7% for gene duplications.
Statistical analysis
Kaplan-Meier estimates of OS and EFS from diagnosis to AML and death were computed. The number of events per 100 people per year (% per year) was calculated together with their 95% confidence intervals (95% CI). Potential risk factors were analyzed by means of a Cox model. No multivariate Cox's model was fit due to the low number of deaths. Hazard ratios and their 95% CI were also determined, utilizing Stata 7 (StataCorp, College Station, TX, USA) for computation.
Results
Patients
The clinical features and outcome of all 57 patients studied and grouped according to FISH results are listed in Tables 1 and 2. FISH detected an occult defect in none of the RARS, 12% of the RA and 21% of the RAEB patients. When IPSS was determined without considering FISH data, the occult defect was seen in none of the low-risk patients, 12% of the int-1 risk and 41% of the int-2 risk. Five out of the nine patients with an abnormal FISH pattern underwent chemotherapy in order to control hyperleukocytosis.
Clinical and biological parameters of the nine patients with an occult abnormality on FISH analysis are summarized in Table 3 . When the FISH abnormal pattern was considered, five out of the nine patients changed their IPSS category: two classified as int-1 became int-2 and three classified as int-2 became high risk. (Table 4) . Metaphase FISH revealed numerical or structural defects in a few cells from five patients. It identified a trisomy 11 ( þ 11), a monosomy 7 (À7) and a trisomy 8 ( þ 8) in one patient each. In all three patients, the abnormal mitotic figures were too poor in quality to make a full karyotype. A structural defect consisting of a TP53 duplication and an ETV6 deletion were detected in one patient each. Interestingly, based on CC results, this last patient was thought to harbor an unbalanced t(12;17) translocation. However, the patient did not present three TP53 signals as expected and the use of a chromosome 17 painting probe excluded the possibility that this last chromosome was involved in the rearrangement. On the contrary, a subsequent hybridization with a painting probe for chromosome 6 demonstrated that the additional chromosome material on 12p13 belonged to number 6 and the der(12) was formally defined as der(12)(12q-ter-12p13::6p21-6pter). The remaining four patients did not show any clonal abnormality on metaphase FISH.
I-FISH detected a clonal defect in nine out of the 57 patients studied (15%). Five patients showed the same defect already revealed by metaphase FISH, while four presented occult defects (5qÀ along with À7, TP53 loss and 20qÀ in case number two, 20qÀ in case three, À5 along with 20qÀ in case four and TP53 loss in case six), which were not detected by metaphase FISH.
Eight of the nine FISH abnormal patients experienced disease progression. In the six evaluable patients, FISH showed an increase in abnormal cells, which were also detected by CC.
Statistical analysis
FISH normal and abnormal patients were comparable for age, sex, type of peripheral cytopenia and FAB subtype; in contrast, blast cell percentage and IPSS were significantly higher in patients with an occult defect (Po10 À3 and P ¼ 0.015, respectively). In addition, disease progression was significantly correlated with an abnormal FISH pattern (Po10 À3 ) (Figure 1 ). The progression rate was 5.7% per year (95% CI: 3.0-11.1) for FISH normal patients vs 49.0% (95% CI: 24.5-98.0) for patients with an occult defect. Those with an occult defect presented an eight-fold greater risk of evolving to advanced MDS or AML (Po10 À3 ) ( Table 5 ). Abnormal FISH was also significantly correlated with death (Po10 À3 ) (Figure 2 ). The death rate was 2.4% per year (95% CI: 0.9-6.5) for FISH normal patients vs 31.6% (95% CI: 15.1-66.4) for patients with an occult defect. 
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These last presented a 15-fold greater risk of death (Po10 À3 ) ( Table 5 ).
Discussion
The aim of the present study was to establish whether FISH, which enables the analysis of interphase cells and the discovery of cryptic defects, might be able to detect occult abnormalities in MDS patients with a normal chromosome pattern on CC analysis and provide additional relevant prognostic information in these patients. Various studies have reported on the ability of FISH to reveal masked karyotype defects. [24] [25] [26] [33] [34] [35] [36] [37] [38] [39] [40] [41] Some have demonstrated that CC and FISH detect chromosome abnormalities at a similar frequency in MDS/AML patients and have concluded that CC is an excellent technique for identifying the most common chromosome defects in these patients, whereas FISH on interphase or mitotic cells has only limited utility. 29, 39, 40 In contrast, other studies have pointed out that FISH identifies minor clonal cell populations marked by À7 or by other structural defects in a significant number of CC normal patients. [22] [23] [24] [25] [26] 33 Two recent reports, which revealed occult karyotype abnormalities in 17.8 and 29.6% of patients, have further stressed the crucial role of interphase/metaphase FISH in the definition of chromosomally normal MDS/AML. 25, 26 In the present study, which includes more RAEB and RAEB-t patients (49 vs 40%) than that of Rigolin et al, 25 the incidence of occult defects was 15%. Our data are also in line with a recent study, which suggested that the loss of chromosome material is a pathogenetic mechanism operative in a fraction of MDS/AML carrying an apparently normal karyotype. 26 In our series, a FISH minor aneuploid cell population (18-25% cells) was identified on clinical diagnosis in three patients (one each with þ 11, À7 and þ 8), who presented at least one monosomic or trisomic cell on metaphase FISH. This datum suggests that CC failed to reveal the chromosome defect not because of its low sensitivity, but rather because of the inability of the dysplastic clone to divide properly in vitro. 19, 34, 35, 41 Previous studies have already shown that À7 and þ 8 are involved in the poor spreading of metaphases and hence cells marked by either defect may be easily missed by CC because of a nonrandom selection made by the technologist. 24, 25, 36, 37 Our incidence of cryptic deletions was 55%, a frequency lower than that of two other studies, 25, 26 but superior to that of one other study. 29 In our series, we observed 20q12, 17p13, 5q13 and 12p13 deletions and a TP53 duplication. In all these patients, metaphase FISH showed that the size of the deletion or size of the duplication was beyond the resolution power of CC. In addition, on clinical diagnosis metaphase FISH identified the deletion in only two cases, suggesting that in the other three patients the dysplastic clone was predominantly formed by quiescent cells. In patient number nine, the help of FISH was absolutely required to define a rearrangement otherwise cryptic on CC.
As far as the prognostic significance of FISH is concerned, this is an important issue not only because the IPSS system 17 is based solely on CC but also because few studies have provided definitive conclusions on the clinical relevance of chromosome defects identified by I-FISH. 25, 26, 33, 40 Considering the former point, our data show that molecular cytogenetics may provide considerable information in chromosomally normal MDS patients. In the present study when CC only was considered, 12 patients (21%) were diagnosed as low risk, 32 (56%) as int-1 risk and 12 (21%) as int-2 risk. In contrast, when FISH results were examined, two individuals classified as int-1 became int-2 and three classified as int-2 became high risk. Therefore, in our patients molecular cytogenetics effected a change in IPSS category.
In order to evaluate the prognostic significance of occult defects, chromosomally normal patients, who based on CC have been initially considered as a whole homogeneous prognostic group, were subdivided into FISH normal and abnormal. As in a FISH in chromosomally normal MDS P Bernasconi et al previous study, 25 these two patient groups differed significantly in crucial characteristics of very well-known prognostic significance, namely marrow blast cell percentage and IPSS risk groups (Po10 À3 and P ¼ 0.015, respectively). Therefore, it could be argued that we compared two noncomparable patient groups; however, we must emphasize that, without the help of FISH, patients with an occult defect would never have been identified and the heterogeneity within the CC category of 'chromosomally normal MDS' would never have been manifested. In addition, many CC studies performed in the 1990s, well before the FISH era, have already documented that the probability of discovering karyotype defects is closely related to marrow blast cell percentage. [6] [7] [8] [9] [10] [11] [12] [13] However, in our series no chromosome abnormality was revealed by CC, despite the high blast cell percentage and FISH was the only parameter that allowed us to identify individuals in the category of CC normal patients who had an adverse clinical outcome. In fact, FISH abnormal patients presented an EFS and an OS significantly inferior to those of normal FISH patients (Po10 À3 ) (Figures 1  and 2 ) and had a risk of AML progression eight-fold superior and death 15-fold superior to normal FISH patients (Table 5 ). Since all the nine patients with a clonal FISH presented the occult defect already at diagnosis, it is unlikely that (in five of them) chemotherapy, aimed at containing tumor mass, might have altered the natural course of their disease; at least it would have lowered the percentage of FISH abnormal cells. Despite these data, the prognostic significance of FISH could not be assessed by multivariate analysis as the number of patients was small and, especially, a close association (colinearity) between the FISH pattern and marrow blast cell percentage was noted. This last datum rendered these two variables impossible to analyze with the same multivariate model.
As far as the clinical impact of occult abnormalities determined by FISH alone is concerned, our study disagrees with recent data that propose that the clinical relevance of clonal karyotype defects is lost when they are revealed by I-FISH, 24, 37, 40, 42 an observation particularly based on occult À7. In fact, this last abnormality seems to be associated with a more indolent clinical course when it is detected by I-FISH and not by CC. However, such an outcome did not occur in patient number seven, an RA, who presented a masked À7 at clinical diagnosis. After 16 months, the patient showed a progressive increase of the monosomic cell population and developed an RAEB (data not shown in Table 3 ), which evolved to RAEB-t after another 29 months. This clinical outcome was also seen in all the other eight patients in whom I-FISH detected the clonal defect earlier than CC and demonstrated an increase in the dysplastic population during follow-up. It should be emphasized that, similar to other studies, 25, 25 on clinical diagnosis each of our FISH abnormal patients presented the occult defect in a significant percentage of interphase cells and not in a single cell. 42 In fact, it has been recently pointed out that single-cell abnormalities may not be clonal or at most indicate the presence of a minor clone well below the level of cytogenetic detection. Obviously, the prognostic significance of such minor clones is at present unclear. 42 In addition, various studies have demonstrated a clonal cell lineage involvement in MDS patients 21, 26, 27 and a mosaicism for some abnormalities, 43 which render the accurate identification of the dysplastic clone even more difficult. All these data have complicated the assessment of I-FISH prognostic significance and it has been indicated that for some patients, continued monitoring with CC and FISH is still the best option. 24, 40, 44 However, considering the relatively lineage-specific distribution of cryptic chromosome lesions
